NovoCureBSP:N2VC34 46 Days Inventory is 101.20 as of Mar. 2026, which is 6% above its 10-year median of 95.67. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 786 Medical Devices & Instruments companies, NovoCure ranks better than 84.1% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). NovoCure's Average Total Inventories for the
three
months ended in Mar. 2026 was R$226 Mil. NovoCure's Cost of Goods Sold for the
three
months ended in Mar. 2026 was R$204 Mil.
Hence, NovoCure's Days Inventory for the
three
months ended in Mar. 2026 was 101.20.
The historical rank and industry rank for NovoCure's Days Inventory or its related term are showing as below:
BSP:N2VC34'
s Days Inventory Range Over the Past 10 Years
Min: 82.37 Med: 95.67 Max: 156.13
Current: 88.74
During the past 13 years, NovoCure's highest Days Inventory was 156.13. The lowest was 82.37. And the median was 95.67.
BSP:N2VC34's Days Inventory is ranked better than 84.1% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs BSP:N2VC34: 88.74
NovoCure's Days Inventory
increased
from Mar. 2025 (90.78) to Mar. 2026 (101.20).
It might indicate that NovoCure's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
NovoCure's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.90.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NovoCure's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.25.
NovoCure (BSP:N2VC34) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NovoCure's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NovoCure's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
NovoCure Days Inventory Related Terms
NovoCure Days Inventory Historical Data
* Premium members only.
The historical data trend for NovoCure's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: Days Inventory Comparison
For the Medical Devices subindustry, NovoCure's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Days Inventory distribution charts can be found below:
* The bar in red indicates where NovoCure's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (BSP:N2VC34) has a Days Inventory of 101.20 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NovoCure and its competitors. This is near median its historical median of 95.67. Over the past decade, NovoCure's Days Inventory has ranged from 82.37 to 156.13. According to the industry distribution chart, NovoCure ranks #125 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is NovoCure's Days Inventory too high?
NovoCure's current Days Inventory of 101.20 is near median its 10-year median of 95.67. Over the past 10 years, this metric has ranged from a low of 82.37 to a high of 156.13. The Medical Devices & Instruments industry median Days Inventory is 179.86. NovoCure's value of 101.20 is 43.7% below this industry median. Based on the distribution chart, NovoCure ranks #125 out of 786 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Days Inventory compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #125 out of 786 companies for Days Inventory. This places NovoCure in the top 16% of its industry — outperforming the majority of peers. The industry median Days Inventory is 179.86. NovoCure's value of 101.20 is 43.7% below this benchmark. Historically, NovoCure's own Days Inventory has ranged from 82.37 to 156.13 over the past decade. While the company's 10-year median is 95.67 vs. the industry median of 179.86, NovoCure has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovoCure's current Days Inventory of 101.20 is 43.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current Days Inventory is 101.20, which is near median its own 10-year median of 95.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current Days Inventory is 101.20, which is near median its 10-year median of 95.67 and 43.7% below the Medical Devices & Instruments industry median of 179.86. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Days Inventory is 101.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
Days Inventory: 101.20 (near median its 10-year median of 95.67)
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
Industry Position: 43.7% below the Medical Devices & Instruments median (#125 of 786)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
